Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1809, Issue 4-6, 2011, Pages 262-268

  Baek, Jin Hyen ^a   Reiter, Chad E N ^a   Manalo, Dominador J ^a   Buehler, Paul W ^a   Hider, Robert C ^b   Alayash, Abdu I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Erythropoietin; Hypoxia inducible factor; Iron chelator

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; COBALT CHLORIDE; DEFEROXAMINE; ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; HYDROXYLATION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; IRON BINDING CAPACITY; IRON CHELATION; KIDNEY; KIDNEY CELL; KIDNEY PARENCHYMA; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN STABILITY; RAT;

ANIMALS; ANOXIA; BINDING SITES; BLOTTING, WESTERN; CELL LINE; COBALT; DEFEROXAMINE; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INJECTIONS, INTRAPERITONEAL; IRON CHELATING AGENTS; KIDNEY; PROCOLLAGEN-PROLINE DIOXYGENASE; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIDEROPHORES;

RATTUS;

EID: 79957710497     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2011.04.010     Document Type: Article

References (43)

1. Elvidge G.P., Glenny L., Appelhoff R.J., Ratcliffe P.J., Ragoussis J., Gleadle J.M. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J. Biol. Chem. 2006, 281:15215-15226.
2. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., Garcia J.G., Semenza G.L. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105:659-669.
3. Stroka D.M., Burkhardt T., Desbaillets I., Wenger R.H., Neil D.A., Bauer C., Gassmann M., Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001, 15:2445-2453.
4. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
5. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995, 270:1230-1237.
6. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5510-5514.
7. 2 tension. Am. J. Physiol. 1996, 271:C1172-C1180.
8. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
9. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., Yang H., Sorokina I., Conaway R.C., Conaway J.W., Kaelin W.G. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13459-13464.
10. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
11. Hirsila M., Koivunen P., Gunzler V., Kivirikko K.I., Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 2003, 278:30772-30780.
12. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
13. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
14. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10430-10435.
15. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7987-7992.
16. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
17. Xia M., Huang R., Sun Y., Semenza G.L., Aldred S.F., Witt K.L., Inglese J., Tice R.R., Austin C.P. Identification of chemical compounds that induce HIF-1alpha activity. Toxicol. Sci. 2009, 112:153-163.
18. Semenza G.L. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009, 114:2015-2019.
19. Smith T.G., Talbot N.P. Prolyl hydroxylases and therapeutics. Antioxid. Redox Signal. 2010, 12:431-433.
20. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2675-2686.
21. Chowdhury R., McDonough M.A., Mecinović J., Loenarz C., Flashman E., Hewitson K.S., Domene C., Schofield C.J. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure 2009, 17:981-989.
22. Nangaku M., Izuhara Y., Takizawa S., Yamashita T., Fujii-Kuriyama Y., Ohneda O., Yamamoto M., van Ypersele C., de Strihou N., Hirayama T.Miyata A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2548-2554.
23. Hoffbrand A.V. Deferiprone therapy for transfusional iron overload. Best Pract. Res. Clin. Haematol. 2005, 18:299-317.
24. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Romeo M.A., Zhao H., Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107:3733-3737.
25. Reeder B.J., Cutruzzola F., Bigotti M.G., Hider R.C., Wilson M.T. Tyrosine as a redox-active center in electron transfer to ferryl heme in globins. Free Radic. Biol. Med. 2008, 44:274-283.
26. Dobbin P.S., Hider R.C., Hall A.D., Taylor P.D., Sarpong P., Porter J.B., Xiao G., van der Helm D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 1993, 36:2448-2458.
27. Epemolu O.R., Singh S., Hider R.C., Damani L.A. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats. Drug Metab. Dispos. 1992, 20:736-741.
28. Singh S., Epemolu R.O., Dobbin P.S., Tilbrook G.S., Ellis B.L., Damani L.A., Hider R.C. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab. Dispos. Mar-Apr 1992, 20(2):256-261.
29. Kageyama Y., Koshiji M., To K.K., Tian Y.M., Ratcliffe P.J., Huang L.E. Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. ASEB J. 2004, 18:1028-1030.
30. 14C]succinate: application to prolyl 4-hydroxylase. Anal. Biochem. 1990, 184:291-297.
31. Baek J.H., Mahon P.C., Oh J., Kelly B., Krishnamachary B., Pearson M., Chan D.A., Giaccia A.J., Semenza G.L. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol. Cell 2005, 17:503-512.
32. Gruber M., Hu C.J., Johnson R.S., Brown E.J., Keith B., Simon M.C. Acute postnatal ablation of Hif-2alpha results in anemia. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2301-2306.
33. Rankin E.B., Biju M.P., Liu Q., Unger T.L., Rha J., Johnson R.S., Simon M.C., Keith B., Haase V.H. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 2007, 117:1068-1077.
34. Scortegagna M., Ding K., Zhang Q., Oktay Y., Bennett M.J., Bennett M., Shelton J.M., Richardson J.A., Moe O., Garcia J.A. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005, 105:3133-3140.
35. Minamishima Y.A., Kaelin W.G. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010, 329:407.
36. Peyssonnaux C., Zinkernagel A.S., Schuepbach R.A., Rankin E., Vaulont S., Haase V.H., Nizet V., Johnson R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 2007, 117:1926-1932.
37. Hider R.C., Porter J.B., Singh H. The design of therapeutically useful iron chelators. The Development of Iron Chelators for Clinical Use 1994, 353. CRC, Boca Raton, FL. R.J. Bergeron, G.M. Brittenham (Eds.).
38. Töndury P., Kontoghiorghes G.J., Ridolfi-Lüthy A., Hirt A., Hoffbrand A.V., Lottenbach A.M., Sonderegger T., Wagner H.P. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br. J. Haematol. 1990, 76:550-553.
39. Hoyes K.P., Hider R.C., Porter J.B. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res. 1992, 52:4591-4599.
40. Hider R.C., Singh S., Porter J.B. Iron chelating agents of clinical significance. Proc. R. Soc. Edinb. 1992, 99B:137.
41. Jia Y., Alayash A.I. Effects of (-)-epigallocatechin gallate on the redox reactions of human hemoglobin. Free Radic. Biol. Med. 2008, 45:659-666.
42. Simonson T.S., Yang Y., Huff C.D., Yun H., Qin G., Witherspoon D.J., Bai Z., Lorenzo F.R., Xing J., Jorde L.B., Prchal J.T., Ge R. Genetic evidence for high-altitude adaptation in Tibet. Science 2010, 329:72-75.
43. Czibik G. Complex role of the HIF system in cardiovascular biology. J. Mol. Med. 2010, 24.